Welcome to our dedicated page for Adaptive Biotechnologies news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies stock.
Adaptive Biotechnologies Corporation (ADPT) is a leader in immune-driven diagnostics, pioneering NGS-based solutions for minimal residual disease detection and immune system mapping. This page serves as the definitive source for official company announcements, financial disclosures, and scientific advancements.
Investors and researchers will find curated updates including earnings reports, regulatory milestones, and partnership developments in precision medicine. Our repository ensures immediate access to press releases about clonoSEQ adoption, clinical trial collaborations, and innovations in immune medicine.
All content is rigorously verified to provide reliable insights into ADPT's strategic direction within the biotechnology sector. Bookmark this page for real-time updates on diagnostic advancements and market-moving developments.
Adaptive Biotechnologies (Nasdaq: ADPT) is set to present over 20 abstracts focusing on its clonoSEQ® Assay for assessing minimal residual disease (MRD) in blood cancers at the upcoming ASCO and EHA meetings. The clonoSEQ Assay is the first FDA-cleared test for MRD in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and B-cell acute lymphoblastic leukemia (B-ALL). The results emphasize its clinical relevance, particularly in monitoring treatment response and potential relapses.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in two upcoming investor conferences. The company will engage in a fireside chat at the William Blair 41st Annual Growth Stock Conference on June 1st at 6:40 a.m. PT and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8th at 12:50 p.m. PT. Interested parties can access the live and archived webcasts via the company’s website. Adaptive Biotechnologies focuses on translating the adaptive immune system's genetics into clinical products for disease diagnosis and treatment.
Adaptive Biotechnologies (ADPT) reported strong financial results for Q1 2021, with revenue of $38.4 million, marking an 84% year-over-year increase. The growth was driven by a 60% increase in sequencing revenue and a 103% increase in development revenue. However, operating expenses rose to $79.7 million, leading to a net loss of $40.6 million, compared to a loss of $31.4 million in Q1 2020. The company anticipates full-year 2021 revenue between $145 million and $155 million, indicating 52% growth at the midpoint.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the BofA Securities 2021 Virtual Healthcare Conference. Management will engage in a fireside chat on May 11 at 8:45 a.m. PT. Interested parties can access the live and archived webcast on the company’s website. Adaptive Biotechnologies focuses on the adaptive immune system, developing diagnostic and therapeutic products for diseases like cancer and autoimmune conditions. The company has three commercial products and a strong clinical pipeline aimed at personalized medicine.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) plans to report its Q1 2021 financial results on May 5, 2021, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, available via webcast. The company leverages the adaptive immune system for disease diagnostics and treatments, boasting three commercial products and a promising clinical pipeline targeting conditions like cancer and autoimmune diseases. The results announcement and the conference call are critical for investors seeking insights into company performance and future growth.
Adaptive Biotechnologies (Nasdaq: ADPT) announced FDA Emergency Use Authorization for its T-Detect COVID test, the first T cell-based diagnostic for detecting prior SARS-CoV-2 infections. The test demonstrated 97.1% sensitivity and 100% specificity. Developed in collaboration with Microsoft, T-Detect COVID allows individuals uncertain about past infections to confirm their status, marking a significant milestone in diagnostic testing. This technology leverages T cells' capabilities for improved disease detection and is expected to pave the way for future diagnostic tests across various diseases.
Adaptive Biotechnologies Corporation announced its participation in the Cowen 41st Annual Healthcare Conference, scheduled for March 2, 2021. The company will engage in a fireside chat at 7:30 a.m. PT / 10:30 a.m. ET.
Interested parties can access a live and archived webcast on their website. Adaptive focuses on utilizing the adaptive immune system to develop clinical products for diagnosing and treating diseases, with a strong emphasis on precision and individual patient care.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its financial results for Q4 and the full year 2020, reporting revenues of $30.2 million for Q4 and $98.4 million for the year, marking increases of 25% and 16% respectively. The company launched T-Detect COVID, a T-cell based test for COVID-19, currently under FDA review for Emergency Use Authorization. Operating expenses rose 54% to $74.4 million in Q4, while net loss increased to $44.6 million. Despite these challenges, cash reserves stand strong at $806.8 million as of year-end.
Adaptive Biotechnologies (Nasdaq: ADPT) announced an expanded collaboration with Labcorp (NYSE: LH) to enhance patient access to its immune-driven clinical diagnostics. This includes commercial agreements for the clonoSEQ® and immunoSEQ® assays and a lab services agreement for the T-Detect COVID test. The collaboration builds on a prior agreement from May 2020, allowing blood collection for clonoSEQ and T-Detect at nearly 2,000 Labcorp patient service centers. Labcorp will promote clonoSEQ in hematology-oncology clinics and prepare to offer T-Detect COVID once it obtains Emergency Use Authorization from the FDA.
Adaptive Biotechnologies (Nasdaq: ADPT) has launched T-Detect COVID, a pioneering T-cell based test for confirming recent or past COVID-19 infections. This innovative test, currently under FDA review for Emergency Use Authorization, reportedly outperforms existing antibody tests. T-Detect is available for patients through nearly 2,000 Labcorp locations or via mobile phlebotomy services. The test leverages research from Microsoft’s TCR-Antigen Map to enhance early diagnosis of COVID-19 and potentially other diseases.